Korro Bio, Inc.

KRRO

US5009461089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
46.4 ^USD	+3.71%		-9.55%	-3.19%

15/05	HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating	MT
14/05	Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	MT

Frequency Therapeutics, Inc. Announces Stepping Down of Carl P. Lebel, Ph.D. as Chief Development Officer, Effective March 31, 2023

February 13, 2023 at 06:46 pm IST

Frequency Therapeutics, Inc. announced that Carl P. LeBel, Ph.D. will be stepping down as the Company's Chief Development Officer, effective March 31, 2023.

Latest news about Korro Bio, Inc.

HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating	15/05	MT
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	15/05	MT
Korro Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Korro Bio, Inc. Announces the Appointment of Kemi Olugemo, M.D. as Chief Medical Officer	15/05	CI
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	25/04	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	25/04	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	25/04	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	25/04	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	25/04	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	25/04	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	25/04	MT
Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.	22/04	CI
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P.	17/04	CI
HC Wainwright Adjusts Korro Bio's Price Target to $115 From $100, Buy Rating Kept	28/03	MT
RBC Boosts Price Target on Korro Bio to $90 From $70 on 'Increased Conviction for A1AT,' Keeps Outperform, Speculative Risk	27/03	MT
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
North American Morning Briefing : Stocks Struggle After New Records	22/03	DJ
North American Morning Briefing : Inflation -2-	15/03	DJ
BMO Capital Initiates Korro Bio With Outperform Rating, Price Target is $120	27/02	MT
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency	07/12	CI
HC Wainwright Starts Korro Bio With Buy Rating, $100 Price Target	04/12	MT
RBC Initiates Korro Bio at Outperform, Speculative Risk With $70 Price Target, Says Lead Program 'May Be Best-in-Class' for A1AT Protein	29/11	MT
Korro Bio, Inc. Appoints Rachel Meyers as Board of Directors, Member of Nominating and Corporate Governance Committee	28/11	CI
Piper Sandler Starts Coverage on Korro Bio with Overweight Rating, $180 Price Target	10/11	MT
Frequency Therapeutics, Inc.(NasdaqCM:FREQ) dropped from NASDAQ Composite Index	03/11	CI

Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Companyâs first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Sector

Biotechnology & Medical Research

Calendar

20/06/2024 - RNA Editing Summit

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

46.4 USD

Average target price

126.2 USD

Spread / Average Target

+172.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KORRO BIO, INC.	-3.19%	430M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research

Korro Bio, Inc.

Equities

KRRO

US5009461089

Biotechnology & Medical Research

Frequency Therapeutics, Inc. Announces Stepping Down of Carl P. Lebel, Ph.D. as Chief Development Officer, Effective March 31, 2023

Latest news about Korro Bio, Inc.

Chart Korro Bio, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research